TenSixty BioSciences

TenSixty BioSciences is a private, pre-clinical stage biotech leveraging an integrated platform of cell models, high-throughput screening, and AI/ML to map the surfaceome of cancer cells and discover novel antibody targets. The company's mission is to identify precise targets and develop transformative biologics for oncology, moving beyond traditional discovery paradigms. Backed by undisclosed world-class investors, TenSixty operates from San Diego, CA, with a listed address in Cambridge, MA, and is building an interdisciplinary team to drive its ambitious goals. The company is currently pre-revenue and focused on platform validation and early pipeline development.

Integrated platform combining biology-first cell models, high-throughput screening technologies, and machine learning/AI to create an atlas of antibody targets on the surface of cancer cells for the discovery of novel therapeutics.

TenSixty operates in the crowded and competitive AI-driven drug discovery space, competing with well-capitalized public companies (e.g., Recursion, Exscientia) and numerous private peers. Its specific focus on the cancer surfaceome and antibody targets also pits it against established antibody discovery platforms and large biopharma internal R&D. Differentiation will hinge on the unique biological insights and data quality from its integrated platform.